What clinicians consider when advising against GLP-1 use during breastfeeding Lack of large, controlled lactation safety trials Unknown effects on infant growth or neurodevelopment Uncertainty about effects on milk supply or composition Elective nature of GLP-1 therapy for weight loss Availability of safer alternatives after breastfeeding ends Why FDA and medical guidance remains cautious FDA and specialty guidance emphasize caution during breastfeeding for several consistent reasons: Insufficient data: FDA labeling states there are inadequate data on GLP-1 medication effects in breastfed infants.,, Milk supply unknowns: It is not known whether GLP-1 medications affect milk supply (volume) or milk composition., Infant vulnerability: Early infancy is a sensitive developmental period, increasing caution when medication effects are unknown. Elective vs essential use: For weight management, potential maternal benefit often does not outweigh theoretical infant risk.,, Do semaglutide and tirzepatide pass into breast milk
Easy order, arrives fast, clean and easy packaging
The Gila monster, in other words, provided one of the first workable templates for a longer-lasting GLP-1-style drug
Irwin, R
Recently, it has been illustrated that HCBP6 (FUNDC2), a mitochondrial outer membrane protein FUN14 structural domain containing 2, can interact with and destabilize SLC25A11, thereby affecting mGSH levels and regulating ferroptosis in the myocardium [61]
Taken together, these findings suggest that alleviation of the weight loss and inflammatory exacerbation associated with UC resulted in a significant decline in mortality in the Si-DSS group compared with that in the Con-DSS group (Table 1)
